$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Effect data of XL184 in patients with RET-rearranged lung cancer
2025-10-19 11:44:20
Check Details
Gyterin is the first targeted drug that can significantly improve the overall survival of patients with common EGFR mutations compared with chemotherapy_ Kanghule
2025-10-19 11:44:20
Check Details
The role of broad-spectrum anticancer drug XL184 in RET-rearranged lung cancer
2025-10-19 11:44:20
Check Details
Giterinib (afatinib) can significantly extend the progression-free survival of patients with brain metastases compared with chemotherapy_ Kanghule
2025-10-19 11:44:20
Check Details
The efficacy of Giterinib (afatinib) in second-line lung squamous cell carcinoma patients is significantly better than that of first-generation TKI_ Kanghule
2025-10-19 11:44:20
Check Details
Where can I buy lung cancer drug XL184? What's the price?
2025-10-19 11:44:20
Check Details
Can XL184 be used to treat patients with MET14 mutated lung cancer?
2025-10-19 11:44:20
Check Details
Gitari can effectively reduce the risk of death and disease progression in advanced squamous non-small cell lung cancer
2025-10-19 11:44:20
Check Details
The emergence of Gitari gives patients with lung squamous cell carcinoma an additional choice
2025-10-19 11:44:20
Check Details
Dosage of anti-cancer drug XL184 for lung cancer
2025-10-19 11:44:20
Check Details
How much does a box of Gitairinib (afatinib) cost after medical insurance reimbursement in 2021?
2025-10-19 11:44:20
Check Details
Safety and effectiveness of Gitairinib (afatinib) in the treatment of lung squamous cell carcinoma
2025-10-19 11:44:20
Check Details
1
2
...
3880
3881
3882
3883
3884
3885
3886
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
2
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
3
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
4
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
5
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
6
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
7
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
8
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
9
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
10
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
11
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
12
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice